Anita T. Shaffer

Associate Director of Editorial, Print
Anita T. Shaffer is your lead editorial contact for OncologyLive®, a twice monthly clinical news publication. A 10-year veteran of MJH Life Sciences™, she has been at the helm of the publication since shortly after joining the company in 2010. Before becoming an oncology journalist, she held a variety of editorial positions at The Times of Trenton, including metro editor. Email: anitashaffer@onclive.com

Articles

First BCMA-Targeting Therapy Debuts in Multiple Myeloma

January 20th 2021

Sagar Lonial, MD, discussed key facets of belantamab mafodotin and potential next steps.

Off-the-Shelf CAR Therapy Shows Early Promise in Multiple Myeloma

December 5th 2020

ALLO-715, an off-the-shelf chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

Mato Presents Sequencing Framework for Crowded CLL Landscape

November 4th 2020

An explosion of therapeutic options for chronic lymphocytic leukemia has resulted in challenging questions about sequencing therapies for patients who progress after frontline treatment with little data to guide optimal therapy selection.

BCMA-Targeting Drugs Take Center Stage in Myeloma

November 4th 2020

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.

Three Key ASCO Studies Showcase Targeted Advances

July 15th 2020

Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.

Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer

May 31st 2020

The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.

CDK4/6 Inhibitors Reach New Benchmarks in Overall Survival in HR+ Breast Cancer

March 6th 2020

The release of new evidence that CDK4/6 inhibition results in survival gains for patients with hormone receptor–positive, HER2-negative metastatic breast cancer marks a new milestone for the therapeutic approach and may help set the stage for expanding use of these agents into earlier clinical settings.

Triplet Targeted Therapy May Signal a New Standard in Metastatic CRC

July 17th 2019

Now, investigators are combining BRAF inhibitors with other targeted therapies in an effort to establish a new chemotherapy-free standard in patients with metastatic colorectal cancer.

Preoperative Immunotherapy Sends Positive Signals in 2 NSCLC Studies

June 3rd 2019

Neoadjuvant immunotherapy demonstrated substantial activity with a favorable toxicity profile in findings from 2 studies of patients with operable early-stage non–small cell lung cancer reported at the 2019 ASCO Annual Meeting.

Antibody-Drug Conjugates Make Headway in TNBC

March 10th 2019

The development of antibody-drug conjugates represents a promising strategy for patients with metastatic triple-negative breast cancer, with early clinical trial results suggesting that novel agents could eventually change the landscape for this patient population.

Promising Debut for PARP Inhibitors Spurs Excitement for Future Therapy

March 9th 2019

The introduction of PARP inhibitors into the breast cancer treatment paradigm is a clinically meaningful advance for patients with germline BRCA1/2 mutations but much more research must be conducted to optimize their use.

Getting It Right in Breast Cancer Means Being More Precise

March 8th 2019

After nearly 30 years as a breast cancer surgeon, Patrick I. Borgen, MD, finds that the most enduring theme in the field is constant change.

Top Developments in Breast Cancer Research Shape the MBCC Agenda

March 8th 2019

The breast cancer field is experiencing rapid advancements in the understanding of disease biology and the development of novel therapeutic strategies for several subtypes, with a clear direction toward personalized or precision medicine.

Biomarkers and Histology Play Key Roles in Frontline Metastatic NSCLC Options

November 13th 2018

In light of recent advancements, the current paradigm for choosing first-line therapy for patients with metastatic non–small cell lung cancer who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology.

Broad Panel NGS Testing Grows in Value for NSCLC

November 11th 2018

Although driver mutations have been identified for significant NSCLC subsets, patients with metastatic disease benefit from broad panel next-generation sequencing testing because of the growing clinical relevance of less common alterations and gene signatures.

Immunotherapy Combos May Shape the Future of HCC Therapy

September 17th 2018

The development of novel immunotherapy combinations is among the most significant trends emerging as part of the next wave of discovery in hepatocellular carcinoma, with several promising regimens incorporating checkpoint inhibitors undergoing testing in phase III studies.

Regorafenib Sustains OS Benefit in RESORCE Trial Update

September 16th 2018

Regorafenib maintained a prolonged overall survival benefit as second-line therapy for patients with advanced hepatocellular carcinoma in a 2-year updated analysis of key findings from the pivotal RESORCE trial.

Independent Review Backs Key REFLECT Findings With Lenvatinib in HCC

September 16th 2018

The positive outcomes that lenvatinib demonstrated as first-line therapy for patients with hepatocellular carcinoma are confirmed in an independent assessment conducted as part of the pivotal, international phase III REFLECT trial.

Second-Line Cabozantinib Proves Effective in HBV+ Liver Cancer

September 15th 2018

Cabozantinib improved survival as second-line therapy for patients with hepatocellular carcinoma who also had a history of hepatitis B virus infection.

Atezolizumab Combo Promising as Frontline HCC Therapy

September 15th 2018

The combination of atezolizumab and bevacizumab demonstrated strong signals of efficacy with a tolerable safety profile as first-line therapy for patients with unresectable or metastatic hepatocellular carcinoma.